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differentiation in murine myoblasts via IGF-1
signaling activation
Pamela Senesi1, Livio Luzi1,2, Anna Montesano1, Nausicaa Mazzocchi3 and Ileana Terruzzi3*Abstract
Background: Betaine (BET) is a component of many foods, including spinach and wheat. It is an essential osmolyte
and a source of methyl groups. Recent studies have hypothesized that BET might play a role in athletic
performance. However, BET effects on skeletal muscle differentiation and hypertrophy are still poorly understood.
Methods: We examined BET action on neo myotubes maturation and on differentiation process, using C2C12
murine myoblastic cells. We used RT2-PCR array, Western blot and immunofluorescence analysis to study the BET
effects on morphological features of C2C12 and on signaling pathways involved in muscle differentiation and
hypertrophy.
Results: We performed a dose–response study, establishing that 10 mM BET was the dose able to stimulate
morphological changes and hypertrophic process in neo myotubes. RT2-PCR array methodology was used to
identify the expression profile of genes encoding proteins involved in IGF-1 pathway. A dose of 10 mM BET was
found to promote IGF-1 receptor (IGF-1 R) expression. Western blot and immunofluorescence analysis, performed in
neo myotubes, pointed out that 10 mM BET improved IGF-1 signaling, synthesis of Myosin Heavy Chain (MyHC)
and neo myotubes length.
In addition, we investigated BET role on myoblasts proliferation and differentiation. During proliferation, BET did not
modify C2C12 proliferative rate, but promoted myogenic induction, enhancing MyoD protein content and cellular
elongation. During differentiation, BET caused an increase of muscle-specific markers and IGF-1 R protein levels.
Conclusions: Our findings provide the first evidence that BET could promote muscle fibers differentiation and
increase myotubes size by IGF-1 pathway activation, suggesting that BET might represent a possible new drug/
integrator strategy, not only in sport performance but also in clinical conditions characterized by muscle function
impairment.
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Betaine (BET) is a zwitterionic quaternary ammonium
compound and it was first discovered in the juice of sugar
beets (Beta vulgaris) by the German chemist Scheibler,
in the 19th century. Now, BET is isolated widely from
microorganisms, plants and animals; it is an important
component of many foods, including wheat, shellfish
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reproduction in any medium, provided the orBET has two main physiologic roles [2]: 1) it is an os-
molyte, which accumulated in tissues to regulate cell
volume and maintain integrity under hyperosmolar stress
[3,4]; 2) it is a methyl donor participating to the methio-
nine-homocysteine cycle. The conversion of homocysteine
to methionine is essential to maintain constant methio-
nine level, detoxify homocysteine and produce the uni-
versal methyl donor S-adenosylmethionine (SAM) [5].
Altered concentration of SAM may influence DNA me-
thylation [6]. Many groups [7,8], including ours [9],
showed that DNA methylation is relevant in controllingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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development.
Some novel studies suggested a possible role of BET
on enhancing exercise performance. First, it has been
hypothesized that BET consumption improves cardiovas-
cular function and thermo regulation while exercising in
a hot environment [10]. Furthermore, in humans, latest
evidence proposed BET as a potential ergogenic aid,
enhancing strength and power performance probably
acting by means of enhancing an increase in skeletal
muscle creatine content [11-14]. Overall, previous reports
suggest that BET supplementation reduces fatigue and
improves muscle function.
Muscle remodeling is a crucial aspect of sport per-
formance. In fact, skeletal muscle is a highly adaptable
tissue that is capable not only to increase its mass in
response to exercise (hypertrophy), but also to form new
fibrils (regeneration) after damage [15-17]. Both muscle
processes, hypertrophy and regeneration, are mediated by
resident muscle precursor cells, termed satellite cells [18].
Satellite cells are mitotically quiescent. Upon a growth
stimulus or injury, satellite cells start proliferating and
turn in committed myogenic cells (myoblasts). Myoblasts
withdraw from the cell cycle and differentiate first; subse-
quently elongating and fusing to repair existing damaged
myofibers or form new myofibers [19,20]. The sequence
of myogenesis depends on highly regulated changes in
gene expression, which are coordinated by the myogenic
regulatory factors (MRFs) [21]. In particular, the MRFs
MyoD and Myf5 act early in myogenesis to determine
myogenic fate and to regulate proliferation; Myogenin
(Myog) and Myf6 act at later stages of myogenesis to
control fusion of myoblasts [22,23]. Other, non-muscle
specific transcription factors, such as p21 and MEF2, are
also important at specific steps of myogenesis [24,25]. All
those regulatory factors coordinate induction of transcrip-
tion structural muscle-specific genes, such as Myosin
Heavy Chain (MyHC, the major structural protein in
myotubes). MRFs and several structural proteins exten-
sively regulate cytoskeletal reorganization, which occurs
before and after fusion of myoblast [26]. Several reports
indicated N-cadherin (N-cad), a member of calcium-de-
pendent cell adhesion molecules, and α sarcomeric actinin
(α act), an actin binding protein, having a central role
in defining myotubes cytoskeletal architecture [27,28].
Among a variety of extracellular and intracellular mole-
cules, Insulin Growth Factor 1 (IGF-1) promotes the che-
miotaxis of satellite cells. The activation of IGF-1 pathway
induces both differentiation and hypertrophy of myoblasts
[29,30]. IGF-1 actions, including the hypertrophic pro-
cesses, are mediated by Akt, a serine/threonine kinase,
which is a downstream target of IGF-1 signaling [31-33].
The purpose of the present study has assess BET ef-
fects during the differentiation and hypertrophic processusing C2C12 murine myoblasts. This cell line, derived
from satellite cells, differentiate in myotubes after serum
removal and provide a useful experimental in vitro model
to study myogenesis and regulation of skeletal mass [34].
Our results indicate that BET promotes muscle fibers
differentiation and myotube hypertrophy via activation
of the IGF-1 signaling pathway.
Methods
Materials
Anti calnexin (H-70), anti MyoD (C-20), anti Myf5 (C-20),
anti Myogenin (D-10), anti Myf6 (C-19), anti IGF-1 (G-
17), anti MyHC (H-300), anti N-cadherin (H-63), anti α-
tubulin (TU-02), anti p21 (C-19), anti IGF-1 receptor β
(C-20), anti Akt (C-20), monoclonal or polyclonal primary
antibodies, HRP-conjugated and rhodamine-conjugated
secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, U.S.A.). Anti α sarco-
meric actinin primary antibody (A7811) and all other re-
agents were purchased from Sigma Chem. Co. (St. Louis,
MO, U.S.A.). In particular, BET used was betaine monohy-
drate (Sigma Chem. Co., St. Louis MO, U.S.A.) and ac-
cording to the manufacturer’s instruction was dissolved in
sterile water. Mouse C2C12 myoblastic cells were pur-
chased from the European Collection of Animal Cell
Cultures (ECACC).
Experimental protocol
C2C12 myoblasts, seeded at 6×102 cells/cm2, were cul-
tured at 37°C in humidified 5% CO2 atmosphere in a
growth medium (GM), containing DMEM supplemented
with 20% (v/v) FBS (fetal bovine serum), 1% penicillin–
streptomycin and 1% L-glutamine. Cell differentiation
was initiated by placing 80% confluent cell cultures in
differentiation medium (DM), containing DMEM supple-
mented with 1% HS (horse serum), antibiotics and 1% L-
glutamine [23].
In our in vitro differentiation model, early myotubes
appeared 48 hours (h) after serum starvation (intermediate
differentiation phase) and neo myotubes formation was
completed after 72 h-96 h (late differentiation phase).
Dose–response study
To study the dose–response relationship of BET stimulus,
we treated neo myotubes with 1, 5 or 10 mM BET for
30 min, 4, 8 and 24 hours (h). Unstimulated neo myotubes
represented control cells.
Myoblasts proliferation and differentiation studies
Based on dose–response results, 10 mM BET concentra-
tion was chosen for C2C12 stimulation. To study C2C12
proliferation and differentiation, myoblasts were grown
to 40-50% confluence in GM and then stimulated with
BET 10 mM. Control cells were maintained in GM or
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morphological changes.
Growth curve
C2C12 myoblasts were plated in 35 mm2 culture dishes
and grown in presence of GM supplement with 10 mM
BET. Control cells were cultured in GM. Experiment
continued until the control cells have reached sub-
confluence (4 days). Medium was daily changed, the
cells were counted using a hemocytometer and the
average values for each single day were used to plot a
growth curve for BET treated and control myoblasts.
RT2-PCR array analysis
We used Mouse Insulin RT2-PCR Array plates (PAMM-
030A, SABiosciences Corporation, Frederick, MD 21703
USA) to study the BET stimuli dose–response. These
plates allow assessing the gene expression involved
in IGF-1 pathway, glucose transport and metabolism.
To analyze the BET action on cell cycle during myo-
blasts proliferation, we used Mouse cell cycle RT2-PCR
Array plates (PAMM-020A, SABiosciences Corporation,
Frederick, MD 21703 USA). These plates allow to deter-
minate the expression of 84 genes, among which genes
encoding cyclins, positive and negative regulators of cell
cycle, as p21 protein. In brief, total RNA was isolated
from C2C12 cells using the RNeasy Plus Mini Quiagen
kit (Quiagen GmbH, Germany) according to the manu-
facturer’s instructions. Total RNA (1 μg) was reverse
transcribed using RT2-First Strand Kit (SABiosciences
Corporation, Frederick, MD 21703 USA). The reverse
transcripts were used as templates for analysis of gene
expression level, using RT2-PCR arrays plates, according
to the manufacturer’s instructions. Each sample was run
in triplicate. We calculated the expression level of the
housekeeping genes, chosen for normalization in the
threshold cycle (Ct), and then the fold-change (ΔΔCt)
for each gene from treatment group compared to the
control group. If the ΔΔCt is greater than 1, the result
may be reported as a fold up-regulation. If the ΔΔCt is
less than 1, the result may be reported as a fold down-
regulation.
Immunoblotting analysis
C2C12 cells were homogenized in lysis buffer (50 mM
Tris/HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,
1 mM sodium orthovanadate (Na3VO4), 1 mM EDTA,
1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin,
1 mg/ml pepstatin) and shaked for 1 h at 4°C. Detergent-
insoluble material was removed from the cell suspension
by centrifugation at 12,000 x g for 30 min. Protein con-
tents were quantified using Bradford method. Aliquots
of 30 μg supernatant proteins from the different sam-
ples were resolved by SDS-PAGE. Electrophoresedproteins were transferred to nitrocellulose membrane
(Protran®, Whatman® Schleicher & Schuell) as described
previously [35]. The membranes were incubated with
specific primary antibodies and then with HRP-
conjugated anti species-specific secondary antibodies.
To confirm equal protein loading per sample, we used
antibody anti calnexin or anti α-tubulin. Immuno-
reactive bands were visualized by an enhanced chemilu-
minescence method (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). Quantitative measurement of im-
munoreactive bands was performed by densitometric ana-
lysis using the Scion Image software (Scion Corporation,
Frederick, MD, USA). The data were then converted to
fold change (FC) of the control.
Immunofluorescence analysis and phase contrast
microscopy
For indirect immunofluorescence, cells were fixed in 4%
paraformaldehyde, permeabilized with 0.2% Triton X-
100, and blocked with PBS containing 1% bovine serum
albumin. Cells were then immunostained with specific
primary antibody and then with rhodamine-conjugated
secondary antibody. Cells were observed using fluores-
cence microscopy (Leica DM IRE2) and images were
captured using IM50 software (Leica Microsystems,
Switzerland). To verify that cells number in all conditions
was superimposable, nuclei were revealed with DAPI
staining. To determinate myotube length dimension, the
average measurement on each slide was generated from
approximately 150 MyHC positive multinucleated myo-
tubes (at least 3 nuclei). In particular, 10 fields were ran-
domly chosen and all MyHC-positive myotubes were
measured. The data were then converted to fold change
(FC) of the control. Live C2C12 cells were examined and
images acquired by phase contrast microscopy using the
same microscope and digital system described above.
Statistical analysis
Data are presented as the mean ± SD. Statistical signifi-
cances were calculated using unpaired t-tests. Results
were considered significant when p ≤ 0.05.
Results
BET dose–response study
This is the first study to asses BET action on muscle
fibers in vitro. Therefore a BET dose–response experi-
ment on neo myotubes was performed. C2C12 cells,
differentiated for 72 h, were treated for additional 24 h
with three different BET doses: 1 mM, 5 mM and 10 mM
(as shown in the experimental protocol: Figure 1A).
Brightfield microscopy revealed that only at the 10
mM BET myotubes length increased (Figure 1B). In
Figure 2E, quantitative data confirmed this initial quali-
tative observation.
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Figure 1 BET dose–response study. A. Graphical representation of myogenesis and simplified design of experimental procedures: neo
myotubes were treated for 24 h with different concentrations of BET: 1 mM, 5 mM and 10 mM. B. Images obtained by brightfield microscopy at
the end of experiment (96 h). C. Insulin-IGF-1 gene expression profiles after 24 h of BET stimuli. D. Analysis of IGF-1 R mRNA: 10 mM BET
significantly increased IGF-1 R mRNA content. E. Immunoblots representative bands of Pro IGF-1 R and IGF-1 R proteins. F.-G. Western blot
analysis revealed that 10 mM BET improved showing Pro IGF-1 R and IGF-1 R protein levels. We performed three independent experiments.
For gene expression analysis data as presented in as fold-change (ΔΔCt) of threshold cycle (Ct) mean ± SD. For immunoblots studies, results are
expressed fold changes (FC) mean ± SD. Significance: a = p≤ 0.05, b = p≤ 0.04, c = p≤ 0.03, d = p≤ 0.02, e = p≤ 0.01 and f = p≤ 0.004. Scale
bar: 200 μm.
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cle hypertrophic process [29,30], we investigated the
molecular mechanisms of BET effect via which BET
carries out its action.
Using Mouse Insulin Pathway RT2-PCR Array, the gene
expression profiles of C2C12 cells stimulated (24 h) with
different BET concentrations (1, 5 and 10 mM) and unsti-
mulated cells were compared (Figure 1C). Data obtained
confirmed that 1 mM and 5 mM BET did not stimulate
the insulin/IGF-1 genes expression network, but 10 mM
BET treatment significantly improved IGF-1 R mRNA
level (Figure 1D, p ≤ 0.004), without any cytotoxic effect.
Those data suggested that 10 mM BET was able to
stimulate cells, activating the IGF-1 R signaling pathway
and subsequential improving myotubes length, without
causing cellular adverse events.
To confirm this hypothesis, we performed Western
blot analysis: neo myotubes were treated with the three
different BET concentrations for 30 min, 4 h, 8 h and
24 h (Figure 1E). IGF-1 R is synthesized as a single poly-
peptide chain (Pro IGF-1 R) that is processed to mature
receptor (IGF-1 R) [33]. As shown in Figure 1F, 1 mM
BET significantly increased Pro IGF-1 R protein content
within 30 minutes and 4 h of treatment (p ≤ 0.02; 4 h: p ≤
0.05), while Pro IGF-1 R amount notably decreased (p ≤
0.03) at the end of the experiment, compared to the con-
trol cells. We observed a similar reduction of Pro IGF-1 R
in neo myotubes stimulated with 5 mM BET for 24 h (p ≤
0.03), while 5 mM BET did not modify Pro IGF-1 R pro-
tein amount at 30 min, 4 h and 8 h. In contrast, 10 mM
BET caused a marked increase of Pro IGF-1 R concentra-
tion after 4 h up to the end of the study (4-8-24 h: p ≤
0.01, p ≤ 0.02, p ≤ 0.04). IGF-1 R protein content analysis
confirmed the results (Figure 1G): 1 mM BET significantly
increased IGF-1 R protein at 30 min only (p ≤ 0.04); 5 mM
BET did not determinate any difference. In contrast,
10 mM BET considerably increased IGF-1 R protein level
during all time-points of the experiment, with the notable
exception of 30 min time-point (4-8-24 h: p ≤ 0.02, p ≤
0.02, p ≤ 0.04). Those data imply that 10 mM BET action
persists beyond 24 h.
BET action on neo myotubes features
To study BET effect on C2C12 neo myotubes morph-
ology, cells were stimulated for 30 min, 4 h, 8 h and24 h, using the three different BET concentrations
(Figure 2A). MyHC protein content was analyzed by
Western blot (Figure 2B). As expected, myotubes treated
with 10 mM BET showed a significant MyHC increase
(24-48-72-96 h: p ≤ 0.05, p ≤ 0.05, p ≤ 0.02 and p ≤ 0.05).
In contrast MyHC protein levels in myotubes supple-
mented with 1 mM or 5 mM BET only did not show stat-
istical difference compared to blank (Figure 2C).
To verify the hypothesis that 10 mM BET could influ-
ence late phase of differentiation program and in par-
ticular hypertrophic process, we studied neo myotubes
size by immunofluorescence analysis (Figure 2D). Neo
myotubes were treated with 10 mM BET and immuno-
stained. Using antibodies against Myf6 and MyHC, a sig-
nificant increase of number and length of myotubes was
detected after stimulation with 10 mM BET compared to
DM cells. Furthermore, the images revealed that 10 mM
BET treated myotubes are characterized by a particular
arrangement of the nuclei to form a ring pattern, which
represents a morphological marker of in vitro muscle
hypertrophy and maturation [36]. Those observations
indicate that 10 mM BET is capable to enhance myotubes
complete formation. To further prove this hypothesis,
we carried out additional immunofluorescence experi-
ments using antibodies against N-cadherin and α sar-
comeric actinin. These are skeletal muscle proteins,
which play a central role in cytoskeleton rearrangement
during myotubes fusion and hypertrophy [27,28]. Im-
munofluorescence data of N-cadherin and α sarcomeric
actinin (Figure 2D) were superimposable to Myf6 and
MyHC images, suggesting that 10 mM BET myotubes
are more numerous and longer compared with control
myotubes. In addition, the length of myotubes treated
with BET 10 mM was significantly greater than the
control (Figure 2E, p ≤ 0.004). Finally, we performed
immunofluorescence assay using antibody against IGF-
1 protein. In neo myotubes treated with 10 mM BET
the number of IGF-1 positive myotubes was higher
than control experiment (Figure 2D).
BET action on myoblasts proliferation
The start of differentiation is closely related to the regu-
lation of cell cycle. Myoblasts in the G1 phase may have
three distinct fates: proliferation, commitment to differ-
entiation or entrance into quiescence [37,38].
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Figure 3 BET action on proliferative myoblasts. A. Simplified design of experimental procedures: myoblasts were grown until 40% confluence
in GM and then the medium was switched in GM with 10 mM BET or in DM. The experiment continued until the cells reached subconfluence.
B. Growth curve trend: 10 mM BET did not influence C2C12 proliferative potential. C. Cell cycle gene expression after 24 h of treatment: the gene
expression profile in the three experimental conditions was similar. D. Representative blot of analyzed proteins are shown. E-F. Western blot
analysis: BET 10 mM significantly improved MyoD amount, but did not modified p21 content. G-H. MyoD immunofluorescence and phase
contrast microscopy images revealed that BET 10 mM myoblasts started to assume an elongated shape, similarly to DM. We performed three
independent experiments. For gene expression analysis data as presented in as fold-change (ΔΔCt) of threshold cycle (Ct) mean ± SD.
Significance: d = p≤ 0.02, e = p≤ 0.01. Scale bar: 200 μm.
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eration (Figure 3A) determining growth curve trend. As
shown in Figure 3B, 10 mM BET did not modify C2C12
proliferative potential. Then, we studied 10 mM BET
effects on cell cycle using Mouse Cell Cycle RT2-PCR
array. This array allows characterization of the ex-
pression of genes that regulate, both positively and ne-
gatively, the progression of cell cycle, the transitions
through the different phases, the DNA replication and
the checkpoints. Cells were cultured in three different
medium for 24 h: GM, GM supplemented with 10 mM
BET and DM. As shown in Figure 3C, 10 mM BET did
not significantly modify cell cycle factors expression
network compared to control experiment and the gene
expression profile in the three experimental conditions
was similar.
We also measured MyoD and p21 protein levels. MyoD
plays a crucial role in achievement and/or maintenance of
myogenic phenotype, while p21 has an important function
in irreversible withdrawal from the cell cycle [39]. As
shown in Figure 3E, 10 mM BET led to a significant
increase in MyoD content, similarly to DM, compared with
control (BET 10 mM: p ≤ 0,02, DM p ≤ 0,01). Consistently
with above mentioned results of cell cycle genes expression
profile, 10mMBET did not modulate p21 protein amount.
Finally, we studied the morphology of myoblasts at the
end of the experiment. Images obtained by immuno-
fluorescence analysis using MyoD antibody and phase
contrast (Figure 3G-H) showed that myoblasts incubated
with 10 mM BET change their morphological aspects: they
loose their characteristic flattened morphology, start to
become polarized and acquired an elongated form. The
morphological changes induced by BET treatment were
comparable to those observed in DM condition.
The present data suggest that BET supplement have a
minimal effect in promoting myogenic acquisition dur-
ing proliferative phase. In contrast, BET-mediated mor-
phological changes, associated with MyoD protein level
increase, are consistent with the effect of the nutrient in
promoting the myoblast commitment to myotube.
BET action on differentiating myoblasts
We investigated BET effect on the several phases of
myogenesis (Figure 4A). Sequential expression of MRFsis important for the successful of myogenesis program
[16,19,21]. In particular, Myf5 is required for commitment
to the myogenic lineage and it is mainly expressed during
early phase, while Myog drives the early of myotubes
genesis and its expression is limited to the intermediate
phase (48 h). To study myogenesis progression in presence
of 10 mM BET, the protein levels of Myf5 and Myog were
measured. As shown in Figure 4C, Western blot analysis
indicated that, in presence of BET, Myf5 maximum incre-
ment was observed 24 h after the induction of differenti-
ation with respect to the control (p ≤ 0.01). In control
condition, Myf5 activation peak was observed at 48 h. In
contrast, in BET treated myoblasts, Myf5 dramatically
decreased at 48 h with respect to the control condition
(p ≤ 0.02). Similarly, in BET myoblasts we observed Myog
expression peak at 48 h (Figure 4D, p ≤ 0.05), followed by
a rapid protein content reduction. In contrast, in control
cells Myog protein level remained unchanged up to 72 h.
Ours results indicate that BET stimulates the kinetics of
Myf5 and Myog synthesis and enhances skeletal muscle
cells differentiation process.
To further define this effect, we analyzed MyHC protein
level. As shown in Figure 4E, during early and intermedi-
ate phases of differentiation (24 and 48 h, respectively)
we did not find a significant difference between MyHC
protein levels in BET treated cells with respect to
control cells. In contrast, we detected a considerable
increase of MyHC protein amount in 10 mM BET cells
during late and terminal phases of differentiation with
respect to the control cells (72 h-96 h: p ≤ 0.05, p ≤
0.003).
During late and terminal differentiation phases, fusion
of myoblast in new myotubes is a central event. Fusion is
a complex mechanism and requires cytoskeletal rearrange-
ment [26,36]. Thus, we determinated N-cad protein con-
tent during differentiation. As shown in Figure 4F, 10 mM
BET markedly increased N-cad protein level at the end of
differentiation (72 h-96 h: p ≤ 0.02, p ≤ 0.05 with respect to
the control). Furthermore, we observed the same results
when we analyzed α sarcomeric actinin protein level
(72 h-96 h: p ≤ 0.01, p ≤ 0.05 vs control, Figure 4G). Thus,
BET could positively regulate the differentiation process
and, in particular, myoblast fusion via an effect on cyto-
skeleton proteins network.
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Figure 4 BET action on differentiating myoblasts. A. Graphical representation of myogenesis and simplified design of experimental
procedures: myoblasts were differentiated in presence of 10 mM BET, differentiation progression was evaluated at early, intermediate and late
phase. B. Representative bands of analyzed proteins by Western blot are shown. C-D. Myf5 and Myog immunoblots indicated that BET could
regulate MRFs kinetics synthesis, accelerating differentiation progression. E-F-G. Western blot analysis showed that BET significantly enhanced
MyHC, N-cad and α act protein content at 72 and 96 h. H-I-J. Western blot studies revealed that, in respect to control, BET 10 mM improved Pro
IGF-1 R levels at 24-48 h, IGF-1 R amount during all phase of differentiation and AKT levels at 72-96 h. K. MyHC immunofluorescence analysis at
48 h indicated that BET could influence neo myotubes features, promoting the acquisition of elongated morphology. Data, obtained from three
independent experiments, are expressed as fold changes (FC) mean ± SD. Significance: a = p≤ 0.05, b = p≤ 0.04, c = p≤ 0.03, d = p≤ 0.02,
e = p≤ 0.01 and f = p≤ 0.003. Scale bar: 200 μm.
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BET was able to modify morphological features of C2C12
cells after 48 h from differentiation induction, when myo-
blasts start to fuse in new myotubes. Using an antibody
against MyHC, we observed that 10 mM BET supplement
induced a higher number of new myotubes, which were
longer than control (Figure 4K). Thus, BET modulates
C2C12 myotubes size promoting cell elongation. The
higher number of MyHC positive myotubes in 10 mM
BET condition confirmed Western blot data and the hy-
pothesis that BET addition to DM enhances the progres-
sion of cell differentiation.
Finally, we evaluated the IGF-1 signaling pathway. As
shown in Figure 4H, BET markedly increased Pro IGF-1
R level at 24 and 48 h (p ≤ 0.01, p ≤ 0.02, respectively).
During all phases, IGF-R amount was significant higher
in BET 10 mM cells compared to control (Figure 4I).
Western blot analysis indicated a significant increment
of AKT, a key kinase of signaling cascade activated by
IGF-1R [31-33] in BET cells after 72 h and 96 h (Figure 4J:
p ≤ 0.04, p ≤ 0.05) with respect to control cells.Discussion
We presently report a set of experiments studying the
role of BET on neo myotubes maturation and differenti-
ation in C2C12 cells.
Recent studies have assessed the potential use of BET as
an ergogenic aid in athletic performance [10-14,40,41].
Previous authors have suggested that BET acts as os-
moprotector and a methyl donor [10,11,13], although no
focused in vitro studies were carried out to investigate the
cellular and molecular mechanisms of BET on skeletal
muscle differentiation and hypertrophy.
At our knowledge, this is the first in vitro study ana-
lyzing BET effect on the C2C12 cells committment, the
differentiation process and the morphology of neo
myotubes.
Firstly, we observed that BET enhances neo myotube
formation, as indicated the MyoD analysis during prolif-
eration phase (Figure 3G) and the kinetics synthesis of
Myf5/Myog during the differentiation phase (Figure 4C-
D). The effect of BET on cytoskeleton protein levels
(MyHC, N-cad, α sarcomeric actinin) and morphologicalanalysis suggests that BET acts on early stage of hyper-
trophy, accelerating it.
Secondly, another novel aspect of our work is consti-
tuted by the finding that BET supplement activates IGF-
1 signaling pathway: this is in accordance with previous
work suggesting that BET could modulate IGF-I signal-
ing [42].
Satellite cells have the function of reserve myoblasts
and C2C12 cells represent the best immortalized model
of them. In response to regular exercise training, skel-
etal muscle can increase its size and contractile power
[16,17,21]. During exercise, satellite cells are activated
and fuse in pre-existing myofibers. Projecting our data to
the in vivo condition, we can speculate that BET, through
IGF-1 signaling pathway activation, may cause hyper-
trophy and eventually ameliorate exercise performance.
Ageing, sedentary lifestyles, immobilization, neuromus-
cular disorders and chronic degenerative diseases (such as
atherosclerosis, cancer and type 2 diabetes), are associated
with loss of skeletal muscle mass and reduced contractive
force [17,43,44]. It has been observed that, in response to
injury, satellite cells can activate and fuse with damaged
myofibers to promote repair and regeneration. Obesity is
characterized by a state of chronic low-grade inflamma-
tion and of high circulating and tissue inflammatory
markers, besides being characterized by relative sarcopenia
[44,45]. BET could influence skeletal muscle regeneration
in positive manner and inflammation process in negative
manner. Recently, Olli et al. demonstrated that extensive
changes in the expression of inflammation-related adipo-
kines in human adipocytes, caused by hypoxia, could be
diminished by the presence of physiological concentra-
tions of BET [45]. Similarly, obesity and ageing are associ-
ated with profound alterations in epigenetic patterns
[46,47]. Future investigations might focus on the effect
of BET on epigenetic profile and on the regulation of
SAM levels.
Several authors suggested that IGF-1 pathway operates
in an autocrine/paracrine mode acting as an intrinsic me-
diator of skeletal muscle repair and adaptation, increasing
the proliferation potential of satellite cells, promoting their
differentiation, enhancing muscle regeneration and even-
tually determining protein synthesis and increase muscle
mass [29,30,33,37].
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activation of IGF-1 pathway in skeletal muscle. In recent
years, the potential effects of BET supplementation in
content of meat livestock were investigated. When added
to animal feeds, BET enhanced lean muscle mass and
reduced the fat [48]. During BET treatment, animals
showed an increase in muscle mass, but also in growth
hormone, IGF-1 and insulin blood concentrations [49-51],
providing additional evidence of the relationship between
BET action on skeletal muscle and IGF-1 signaling.
Most importantly, very recently, Apicella et al., have
demonstrated that BET supplementation significantly
increased IGF-1, AKT content as well as the respective
anabolic signaling environment in skeletal muscle of
trained men [52].
Conclusions
In summary, our in vitro work provides the first evidence
of possible BET positive action on skeletal muscle myo-
blasts differentiation, in particular on the progression of
the differentiation process and on myotubes morphology.
This effect is at least partially mediated by the IGF-1 sig-
naling activation. Our in vitro results are consistent with
in vivo data obtained in livestock and in humans and may
contribute the bench proof for a use of BET as a dietary
supplement in humans.
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